Sino Biopharmaceutical Limited (01177.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

13.0x

EV/EBITDA

8.5x

Market Cap

HKD 99.64B

MomentumView details →

1D Return

−0.98%

YTD Return

−10.44%

RSI (14)

58.7

ValuationView details →

P/E (Fwd)

13.0x

EV/EBITDA

8.5x

Market Cap

HKD 99.64B

RSI (14)

58.7

MomentumView details →

1D Return

−0.98%

YTD Return

−10.44%

ProfitabilityView details →

Gross Margin

82.43%

Net Margin

7.09%

EBITDA Margin

30.89%

ROE (TTM)

7.34%

ROA (TTM)

2.87%

Asset Turnover

0.41x

GrowthView details →

Revenue YoY

+10.26%

EPS YoY

−38.48%

FCF YoY

+78.69%

Revenue CAGR 3Y

+6.95%

EPS CAGR 3Y

+5.73%

EBITDA YoY

+70.30%

EarningsView details →

EPS (Actual)

HKD 0.22

EPS Surprise

58.56%

Beats (12Q)

1/12

Next Q EPS Est

HKD 0.13

Avg Surprise (4Q)

58.56%

Rev Surprise

0.68%

Capital & dividendView details →

Debt/Equity

0.53x

Current Ratio

1.63x

Quick Ratio

1.56x

Div Yield

2.17%

Div Rate

HKD 0.12

Div Growth 1Y

+33.33%

Financials snapshotView financials →

Revenue (TTM)

33.70B

Net Income (TTM)

2.39B

Op. CF (TTM)

6.13B

Next earningsApr 1, 2027 →

Latest newsMore news →

China Biopharmaceuticals' subsidiary Chia Tai Tianqing received FDA approval for its investigational new drug TQB6426, a GPC3 antibody-drug conjugate for advanced malignant tumors, to proceed with clinical trials.1d ago

CIPLA and SBP Group signed an exclusive licensing agreement for the HER2 bispecific antibody-drug conjugate TQB2102.4d ago

Similar companies

iNtRON Biotechnology, Inc.048530.KQ MedPacto, Inc.235980.KQ Vaxcell-Bio Therapeutics Co., Ltd.323990.KQ Innovent Biologics, Inc.01801.HK ORIENT BIO Inc.002630.KS Akeso, Inc.09926.HK Find similar companies →

Latest newsMore news →

China Biopharmaceuticals' subsidiary Chia Tai Tianqing received FDA approval for its investigational new drug TQB6426, a GPC3 antibody-drug conjugate for advanced malignant tumors, to proceed with clinical trials.1d ago CIPLA and SBP Group signed an exclusive licensing agreement for the HER2 bispecific antibody-drug conjugate TQB2102.4d ago China Biologic Products' subsidiary Laixinnuo Medical Technology received clinical trial approval from China's NMPA for its innovative drug LM-364 (Nectin-4 TME ADC) for advanced solid tumors, following FDA approval in April and trial initiation in Australia.7d ago